MedLumics Proprietary Technology to be presented at 26th Annual International AF Symposium
- MedLumics is developing a unique real-time, optically-guided ablation catheter to improve treatment of Atrial Fibrillation by RadioFrequency Ablation and Pulsed Field Ablation
- Presentation on Direct Lesion Assessment using Photonics during AF Ablation
News provided by
Share this article
Share this article
MADRID, Jan. 28, 2021 /PRNewswire/ -- MedLumics, a privately held medical technology company developing AblaView®, an optically-guided RadioFrequency (RF) catheter ablation system for the treatment of Atrial Fibrillation (AF), announced today the first public communication on its technology using photonics during AF ablation at the upcoming 26
Renowned cardiologist Dr Atul Verma, FHRS, FRCPC, Director of Arrhythmia Services at Southlake Regional Health Care Centre in Newmarket, Ontario, Canada will present during
TM in the ablation treatment of persistent atrial fibrillation (AF) Pulmonary vein isolation (PVI) plus STAR-guided ablation demonstrates superior ity to either PVI alone or when PVI was combined with other ablation techniques London, 26th January 2021: RHYTHM AI Ltd, a UK company focused on the treatment of Atrial Fibrillation (AF), today announces publication of a clinical outcome study for its STAR (Stochastic Trajectory Analysis of Ranked signals) Mapping system, which is designed to improve outcomes in patients receiving ablation treatment for persistent AF. The article in the peer-reviewed journal, Journal of Cardiovascular Electrophysiology is titled "Ablation guided by STAR Mapping, in addition to pulmonary vein isolation, is superior to pulmonary vein isolation alone or in combination with CFAE/linear ablation for persistent AF".*
Share this article
Share this article
MENLO PARK, Calif., Jan. 7, 2021 /PRNewswire/ -- Ablacon, Inc., an Ajax Health-backed company, announced the close of a $30 million Series B financing, with Zeus Health joining as new lead investor. Ablacon also announced the addition of Dr. David Haines, Professor of Cardiovascular Medicine at Oakland University William Beaumont School of Medicine and Director of the Heart Rhythm Center at Beaumont Health, Royal Oak, MI, to the company's scientific advisory board (SAB).
Ablacon plans to use the new funds to advance the company's product portfolio and continue expanding patient access to the CE Marked Ablamap® system. Dr. Haines will join the rest of the Ablacon all-star SAB to work with the company to map out a clinical research strategy to methodically demonstrate the promise of using Electrographic Flow and Ablamap to improve patient care in atrial fibrillation (AF).